<DOC>
	<DOCNO>NCT00554606</DOCNO>
	<brief_summary>This study assess long-term safety tolerability ACZ885 patient rheumatoid arthritis , well long-term efficacy , long-term preservation and/or improvement joint structure bone mineral density , long term maintenance health-related quality life .</brief_summary>
	<brief_title>Long-term Efficacy , Safety Tolerability ACZ885 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients ( male nonpregnant , nonlactating female ) complete core CACZ885A2204 , CACZ885A2206 , CACZ885A2207 study without serious severe drugrelated adverse effect may enter extension study upon sign informed consent Patients continue treatment extension consider appropriate treat physician . Patients noncompliant demonstrate major protocol violation core study . Patients complete / discontinue core study . Patients drug relate serious adverse event severe adverse event . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anit-interleukin-1 beta</keyword>
	<keyword>ACZ885</keyword>
</DOC>